reza at liebertpub.com
Fri May 1 01:41:41 EST 1998
I would like to invite you to the upcoming conferences
Transgenics and Cloning.: Commercial Opportunities and
The Second Annual-Mammalian Cloning: Implications for
Science and Society, Washington, D.C. June 24 - 27, 1998.
This unique opportunity has been structured to allow the
broadest possible interactions between leaders in the
fields of transgenics, cloning and germline genetic
engineering. Participants in these back-to-back events
will explore the tremendous commercial opportunities balanced
with ethical considerations. The conference co-chairs are
Ian Wilmut, Ph.D., The Roslin Institute, W. French Anderson, M.D.,
Director, Gene Therapy Laboratories, USC/ School of Medicine
and Lee Silver, Ph.D., Department of Molecular Biology,
Princeton University. Keynote presentation: Gina Kolata of
the New York Times, author of Clone: The Road to Dolly and
the Path Ahead
Intellectual Property Law
Gerard van Beynum, PhD.,
Brigitte Boiselier, PhD.,
PPL Therapeutics, Inc.
Hortense Dodo, PhD
Alabama A&M University, Dept.
of Food and Animal Industries
Tanja Dominko, Ph.D.,
Oregon Primate Research Laboratory
Howard Ducharme, D. Phil.
The University of Akron, Dept. of
Yann Echelard, PhD
Associate Director of Embryology
OttoH. Postma, Pres. & CEO
Lee Silver, Ph.D.
Professor, Dept. of Molecular Biology,
Mohamed Shahin, Ph.D.
Ain Shams University, Egypt
Steven Stice, PhD, CSO
Advanced Cell Technology
Gregory Stock, PhD
Director, Science, Technology
and Society Program, UCLA,
Institute of Geophysics and Planetary Physics
Richard Warburg, Esq.
Lyon & Lyon
Kevin T. Fitzgerald, S.J., Ph.D.
Loyola University Medical Center
Henry N. Geraedts, Ph.D.
President and CEO
Chromos Molecular Systems, Inc.
Glenn McGee, Ph.D.
Professor, University of
Pennsylvania Health System, Center for Bioethics
J. Robert Nelson
Senior Research Fellow,
The Institute of Religion, Texas Medical Center
Erik Parens, Ph.D.
Associate for Philosophical Studies,
The Hastings Center
Professor, University of Alabama at Birmingham
Dale Schwartz, CEO
->Human Cloning for Enhancement Purposes
->Prospects for Human Germline Engineering
->Cloning and the Soul: Traditional and Contemporary Options
->Applying Somatic Cell Nuclear Transfer to Humans
->Dimensions of a Regulatory Framework for Clinical Cloning
->The First Human Cloning Company
->The Impact of Nuclear Transfer on The Commercial Transgenic
Production of Recombinant Proteins
->Arguments Against Human Cloning
->Cloned Transgenic Cattle and Pigs
->Artificial Chromosome Technology
->Dolly, Polly and Cloning: The Role of Nuclear Transfer
Technology in Transgenic Protein and Peptide Production,
Scaleup and Commercialization
->Transgenics and Cloning: New Commercial Opportunities for
Biotech and Large Pharmaceutical Companies
-> Intellectual Property and Animal Cloning
-> Intellectual Property Law Patenting Human
-> Gene Therapies* in the United States
* Under the Proposed European Biotech
->Transgenics and Cloning in Non-Human Primates -
Possibilities for Improving Human Health
We would be pleased to send or fax a full program to you.
Please contact us by E-mail at <hmatysko at liebertpub.com>,
or <mhurley at liebertpu.com>, or 1800 5 BIOCON ext. 652.
The conference is co-sponsored by Genetic Engineering News,
published by Mary Ann Liebert, Inc. If you would like a
complementary copy, please contact by E-mail at
<vcohn at liebertpub.com>.
We would also appreciate it if you could post that
Transgenics and Cloning.: Commercial Opportunities and The
Second Annual - Mammalian Cloning: Implications for Science
and Society, will take place June 24- 27, 1998 at the J.W.
Marriott, Washington, D.C., The full program of this conference
is available on request. Please call 800 5-BIOCON or
(914) 834-3100 (ext 652) or by E-mail at <hmatysko at liebertpub.com>,
or <mhurley at liebertpub.com>.
Limited sponsorship and exhibiting opportunities are still
available. Please contact us.
More information about the Bionews